Q3 EPS Estimates for Organigram Increased by Analyst

Organigram Holdings Inc. (TSE:OGI) – Investment analysts at Alliance Global Partners raised their Q3 2025 earnings estimates for Organigram in a research note issued to investors on Tuesday, February 11th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Alliance Global Partners also issued estimates for Organigram’s Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.26) EPS and FY2026 earnings at ($0.08) EPS.

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity Group reduced their price target on shares of Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a research report on Monday, December 9th. ATB Capital reduced their price target on shares of Organigram from C$5.25 to C$3.50 in a research report on Tuesday, December 17th.

Organigram Stock Down 5.7 %

Shares of TSE:OGI opened at C$1.81 on Friday. The company has a debt-to-equity ratio of 3.07, a quick ratio of 2.62 and a current ratio of 3.36. The company has a market cap of C$223.61 million, a PE ratio of -3.83, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. Organigram has a 52 week low of C$1.80 and a 52 week high of C$3.95. The firm has a 50 day simple moving average of C$2.24 and a 200 day simple moving average of C$2.31.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.